RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles

被引：32

作者：

Luo, Guopei ^{[1
]}

Jin, Chen ^{[1
]}

Long, Jiang ^{[1
]}

Fu, Deliang ^{[1
]}

Yang, Feng ^{[1
]}

Xu, Jin ^{[1
]}

Yu, Xianjun ^{[1
]}

Chen, Wei ^{[2
]}

Ni, Quanxing ^{[1
]}

机构：

[1] Fudan Univ, Pancreat Dis Inst, Dept Gen Surg, Huashan Hosp, Shanghai, Peoples R China

[2] Fudan Univ, Sch Pharm, Shanghai 200433, Peoples R China

来源：

CANCER BIOLOGY & THERAPY | 2009年 / 8卷 / 07期

基金：

中国国家自然科学基金;

关键词：

nanoparticle; RNA interference (RNAi); poly(d; l-lactic-co-glycolic acid) (PLGA); poloxamer; methyl-CpG binding domain protein 1; gene carriers; METHYLATION PATTERNS; DNA; CARRIERS; PROFILE; GENES;

D O I：

10.4161/cbt.8.7.7790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methyl-CpG binding domain protein 1 (MBD1) is a transcriptional regulator that binds methylated CpG islands of tumor suppressor genes and represses their transcription. In a former study, we found high expression of MBD1 in pancreatic cancer cell lines and tissues which may play an important role in the development of pancreatic cancer. In the present study, we incorporated the siRNA sequence of MBD1 plasmid into a PLGA: Poloxamer carrier to test the therapeutic effect of this compound on BxPC-3 human pancreatic cancer cells. We found that an MBD1 siRNA plasmid can be successfully transfected into tumor cells and the MBD1 nanoparticle compound can inhibit cell growth and induce apoptosis. The MBD1 nanoparticle is a promising candidate for gene therapy of pancreatic cancer in vitro.

引用

页码：594 / 598

页数：5